Primary Record
XL765
- In stock
- 6,709 g
- Purity
- 98.4 %
- CAS
- 1349796-36-6
Compound Identifiers & Properties
- CAS
- 1349796-36-6
- PubChem CID
- 49867926
- SMILES
- CC1=C(C=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC3=NC4=CC=CC=C4N=C3NC5=CC(=CC(=C5)OC)OC)OC
- Canonical SMILES
- COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1
Names & Synonyms
- XL765
- voxtalisib
- Voxtalisib Analogue
- Voxtalisib-Analog
- 1349796-36-6
- XL765 Analogue
- PI3K-IN-1
- voxtalisib analog
- XL-765
- 1123889-87-1
- XL-147 derivative 1
- Exelixis pI3K inhibitor
- SAR245409 analogue
- SAR245409
- C31H29N5O6S
- D01PGR
- D05NDW
- D0I3KU
- XL-765 ANALOGUE
- SAR245409 (XL765)
- MFCD18252649
- XL 765
- CHEMBL3349370
- cc-497
- MLS006011009
- orb419544
- XL-765,SAR245409
- GTPL7964
- SCHEMBL8739843
- XL765-II
- SAR-245409
- SCHEMBL29374434
- CHEBI:71958
- KS-00001CVG
- AOB2912
- EX-A234
- EX-A278
- DTXSID401356804
- GLXC-04824
- HMS3295O01
- HMS3654D20
- BCP02276
- BCP32612
- CS-0230
- N-(4-(N-(3-((3,5-dimethoxyphenyl)amino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-methoxy-4-methylbenzamide
- N-[4-({3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl}sulfamoyl)phenyl]-3-methoxy-4-methylbenzamide
- ABP000903
- CS-230
- NSC755808
- NSC768100
- NSC800992
- s1523
- XL765/SAR245409
- ZINC70471842
- XL-765, SAR245409
- AKOS025401936
- CCG-270195
- NSC-755808
- NSC-768100
- NSC-800992
- RL00494
- SDCCGSBI-0654377.P001
- Voxtalisib (SAR245409, XL765)
- Voxtalisib (XL765, SAR245409)
- NCGC00346541-01
- NCGC00346541-08
- AC-27422
- AC-33163
- BC600525
- DA-45835
- HY-12068
- LS-15306
- SC-95474
- SC-95576
- SMR004702807
- AB0033716
- A3941
- A5634
- FT-0753985
- FT-0761386
- N-[4-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-3-methoxy-4-methylbenzamide
- SW218114-2
- X7418
- Voxtalisib (SAR245409, XL765) Analogue
- A10997
- W-5739
- SAR245409/MSC1936369B combination therapy
- A887772
- BRD-K75308783-001-01-3
- BRD-K75308783-001-07-0
- Q27089152
- 934493-76-2
- RTK inhibitors (cancer), Shenzhen Chipscreen Biosciences
- XL 765, 1123889-87-1
- N-[2-[(3,5-Dimethoxyphenyl)amino]quinoxalin-3-yl]-4-[(4-methyl-3-methoxyphenyl)carbonyl]aminophenylsulfonamide
- N-[4-[[[3-[(3,5-dimethoxyphenyl)amino]-2-quinoxalinyl]amino]sulfonyl]phenyl]-3-methoxy-4-methyl-benzamide
- CS-0230 series (multi receptor tyrosine kinase inhibitors, cancer)
- XL765;XL 765;SAR245409;SAR-245409;SAR 245409;Voxtalisib Analogue
- CS-0230 series (multi receptor tyrosine kinase inhibitors, cancer), Shenzhen Chipscreen
- Benzamide, N-?[4-?[[[3-?[(3,?5-?dimethoxyphenyl)?amino]?-?2-?quinoxalinyl]?amino]?sulfonyl]?phenyl]?-?3-?methoxy-?4-?methyl-
- N-(4-{[3-(3,5-Dimethoxyanilino)-2-quinoxalinyl]sulfamoyl}phenyl)-3-methoxy-4-methylbenzamide
- N-[4-({[3-(3,5-Dimethoxyanilino)-2-quinoxalinyl]amino}sulfonyl)phenyl]-3-methoxy-4-methylbenzamide
- N-[4-[[[3-[(3,5-dimethoxyphenyl)amino]-2-quinoxalinyl]amino]sulfonyl]phenyl]-3-methoxy-4-methyl-benzamide|||SAR-245409
- N-[4-[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]sulfamoyl]phenyl]-3-methoxy-4-methyl-benzamide
- Voxtalisib-Analog;PI3K-IN-1;XL765-Analog; XL 765-Analog; XL-765-Analog; SAR245409-Analog; SAR245409-Analog; SAR 245409-Analog